CA-BIOCYTOGEN
30.8.2022 02:01:34 CEST | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") and TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), today jointly announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for the initiation of a Phase 1/2 clinical study of YH001 in combination with envafolimab and doxorubicin for the treatment of sarcoma patients, including patients who have not received prior therapy.
The Phase 1/2 trial will assess the safety and efficacy of YH001 and envafolimab in patients with the rare sarcoma subtypes of alveolar soft part sarcoma and chondrosarcoma and assess the safety and efficacy of the combination of YH001, envafolimab and doxorubicin in the common sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma.
“YH001 was discovered using Biocytogen’s evidence-based in vivo drug efficacy screening platform and has demonstrated a favorable safety profile and promising anti-tumor activity in combination with a PD-1 antibody in an earlier phase 1 clinical study,” said Rong Chen, M.D., Ph.D., VP of Biocytogen, CEO and CMO of Eucure Biopharma. “As an antibody targeting the validated checkpoint CTLA-4, YH001 is expected to play a very important role in immune-oncology therapy. We are glad to learn that the combination therapy of YH001 + envafolimab and doxorubicin received IND approval by the FDA.”
“We are pleased to receive approval from the FDA to initiate our triplet combination therapy study in sarcoma, which includes our potentially best-in-class CTLA-4 antibody YH001 and the only subcutaneous checkpoint inhibitor approved anywhere in the world, envafolimab,” said Charles Theuer, M.D., Ph.D., TRACON’s Chief Executive Officer. “We look forward to enrolling patients in this study and giving patients additional options for their sarcoma treatment.”
About YH001
YH001 is an IgG1 antibody targeting CTLA-4 that was invented by Biocytogen, the parent company of Eucure Biopharma, and licensed by TRACON. YH001 has shown enhanced antibody dependent cellular cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) in vitro when compared with ipilimumab. In preclinical studies YH001 demonstrated superior T cell activation and superior tumor growth inhibition activity compared to ipilimumab as a single agent and when combined with a PD-(L)1 antibody in human transgenic mouse tumor models. In these models, single agent YH001 depleted regulatory T cells and increased CD8+ T cells in tumor tissue. YH001 has been dosed as a single agent in a Phase 1 trial in China (NCT04699929) and in combination with the PD-1 antibody toripalimab in a Phase 1 trial in Australia (NCT04357756).
About Eucure Biopharma
As a wholly owned subsidiary of Biocytogen, Eucure Biopharma undertakes the mission of clinical development for Biocytogen’s R&D pipelines. Relying on a strong clinical development team and extensive clinical development experience, Eucure Biopharma focuses on antibody drug therapy for oncology and other indications. The company has established a product pipeline for more than 10 targets, with two products in launched phase II multi-regional clinical trials (MRCT) and two in phase I. For details, please visit www.eucure.com.
About Biocytogen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of antibody drugs. The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai and Boston, USA. For more information, please visit www.biocytogen.com.cn.
About TRACON
TRACON is a clinical-stage biopharmaceutical company utilizing a cost-efficient, CRO-independent, product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; YH001, a potential best-in-class CTLA-4 antibody in Phase 1 development; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships through a profit-share or revenue-share partnership, or through franchising TRACON’s product development platform. TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the United States or who wish to become CRO-independent. To learn more about TRACON and its product pipeline, visit TRACON’s website at www.traconpharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220829005548/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Announces First-Quarter 2026 Results24.4.2026 12:50:00 CEST | Press release
Revenue of $8.72 billion increased 3% year on year GAAP EPS of $0.50 decreased 14% year on year EPS, excluding charges and credits, of $0.52 decreased 28% year on year Net income attributable to SLB of $752 million decreased 6% year on year Adjusted EBITDA of $1.77 billion decreased 12% year on year Cash flow from operations was $487 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the first-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422463846/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChange Mar. 31, 2026 Dec. 31, 2025 Mar. 31, 2025 Sequential Year-on-year Revenue $8,721 $9,745 $8,490 -11% 3% Income before taxes - GAAP basis $956 $943 $1,063 1% -10% Income before taxes margin - GAAP basis 11.0% 9.7% 12.5% 129 bps -156 bps Net income attributa
Gamma Waves Launches: Playing Tomorrow’s Game Today24.4.2026 11:15:00 CEST | Press release
Gamma Waves, a permanent capital investment company, with the ambition to build an innovative sport-focused platform, launches today. Based in Amsterdam, the company was founded by Andrea Agnelli, Rocco Benetton and Giorgio Chiellini, with the aim of creating new value across: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424892627/en/ Gamma Waves Partners launched today, here is the team, including founders, Andrea Agnelli, Rocco Benetton and Giorgio Chiellini, along with Chief Investment Officer, Kyang YungSport IPs (Intellectual Properties): assets in globally captivating sectors such as basketball, hockey, cricket, tennis, baseball, rugby, etc., offering unique reach and credibility; Sports Tech: high-quality sports technology products that often struggle to scale because, on their own, they lack sufficient incentives and distribution to break through alongside IPs. Gamma Waves aims to bridge this gap by building a m
Sovereign AI for the World: Cohere and Aleph Alpha to Form Global AI Powerhouse as Nations and Enterprises Demand Control Over Their Technology24.4.2026 11:15:00 CEST | Press release
The companies of Schwarz Group Commit $600M (€500M) in Structured Financing to Further Accelerate Germany-Canada Sovereign AI Venture Cohere and Aleph Alpha, two trusted sovereign AI providers for governments and regulated industries, today announce their plan to join forces. This transatlantic alliance would combine Cohere’s global AI scale with Aleph Alpha’s strong research excellence and deep institutional relationships, forging a globally competitive AI champion backed by their Canadian and German ecosystems. The initiative reflects a shared vision: To provide the world with an independent, enterprise-grade sovereign alternative in an era of growing AI concentration and to ensure that organizations do not need to relinquish control over their own AI stack. The planned combined entity1 will function as a transatlantic AI powerhouse, anchored in Germany and Canada, empowering organizations to choose, deploy and govern AI according to local laws, cultural contexts, and institutional r
Porsche Sells Bugatti Stake to BlueFive Capital24.4.2026 10:00:00 CEST | Press release
Porsche has agreed to sell its equity stake in Bugatti Rimac. Porsche and Rimac Group established Bugatti Rimac as a joint venture in 2021 to serve as home to the iconic Bugatti brand. In this joint venture, Porsche holds a minority stake of 45%, Rimac Group owns 55%. Porsche also holds a 20.6% stake in Rimac Group. As part of the transaction announced today, Porsche will fully divest its equity stakes in Bugatti Rimac and Rimac Group to a HOF Capital-led consortium. This includes BlueFive Capital as its largest investor, as well as a group of institutional investors across the US and EU. Following completion, Rimac Group is set to take control of Bugatti Rimac and form a strategic partnership with BlueFive Capital and HOF Capital to support its continued growth. Hazem Ben-Gacem, Founder and Chief Executive of BlueFive Capital: “Bugatti is a monument to automotive obsession, born from Ettore Bugatti’s pursuit of beauty and performance combined. BlueFive Capital approaches this opportun
NIQ and INTAGE HD Partner to Expand Retail Measurement Across Japan and Global Markets24.4.2026 04:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, and INTAGE HOLDINGS Inc. (hereafter "INTAGE HD"), a leading market research company in Japan, today announced a mutual sales partnership to expand access to retail measurement insights between Japan and global markets. Through the collaboration, NIQ and INTAGE HD bring together complementary strengths— INTAGE HD’s deep local retail store panel data and insights into the Japanese domestic market, and NIQ’s global and regional retail store panel data and insights into various international markets—to enable better comparison and understanding of market performance and trends across countries and regions. This collaboration enhances both companies’ ability to support clients with more consistent and comparable insights, helping clients unlock growth opportunities across markets. The collaboration enables global clients to access INTAGE HD’s nationwide retail store panel data in Japan (SRI+ and SRI+EC) to support market entry
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom